JSON
Siaw JT, Claeys A, Lai WY, Borenäs M, Hilgert E, Bekaert SL, Sanders E, Kaya I, Van Dorpe J, Speleman F, Durinck K, Hallberg B, Palmer RH, Van den Eynden J
iScience 29 (4) 115236 [2026-04-17; online 2026-03-05]
High-risk neuroblastoma is characterized by MYCN amplification and high MYCN or MYC gene expression. These patients have a poor prognosis and there is an urgent need for more effective drugs. While strategies to develop inhibitors that directly target the MYC proteins have remained largely unsuccessful, recent preclinical studies have identified ATR, a key protein of the DNA damage response, as a promising alternative therapeutic target. Here, we identified a strong RUVBL1 and RUVBL2 signature in transcriptomics data derived from different MYCN-driven mice tumors treated with ATR inhibitors. The RUVBL proteins form a complex with ATPase activity that has broad cellular functions and we demonstrate that pharmacological inhibition of this protein complex results in a strong reduction of MYC(N) signaling, cell-cycle arrest, DNA damage, and apoptosis. We confirmed the association with MYCN and identified the RUVBL genes as independent prognostic biomarkers in human primary neuroblastoma data.
NGI Stockholm (Genomics Applications) [Service]
NGI Stockholm (Genomics Production) [Service]
National Genomics Infrastructure [Service]
PubMed 41940329
DOI 10.1016/j.isci.2026.115236
Crossref 10.1016/j.isci.2026.115236
pmc: PMC13049659
pii: S2589-0042(26)00611-5